Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSE: Panitumumab Rechallenge in mCRC
NCT03992456Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Apr 2020
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing Panitumumab with Standard of Care (2 arms). Primary endpoint: Overall Survival at 2 years. Started Apr 2020; status: active, not recruiting.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03992456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992456.